ScripDomain Therapeutics S.A. is advancing its first wholly owned drug candidate, DT-9081, into in-human studies later this year, drawing upon its G protein-coupled receptors (GPCR) expertise built up thr
ScripVenture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting the
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Kite Will Partner With HiFiBiO On AML D
ScripGE Healthcare and Vanderbilt University Medical Center are working together to combine immuno-oncology with precision medicine through a five-year collaboration unveiled Jan. 6, to determine which